Yükleniyor... / Loading...
Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract
Bu çalışma, kronik obstrüktif akciğer hastalığı (chronic obstructive pulmonary disease, COPD) olan hastalarda alt solunum yollarındaki bakterilerin azaltılması yoluyla akut alevlenmelerin önlenmesini incelemektedir. Bunun için ağızdan probiyotikler, inhale (soluma yoluyla) amikasin ve birleşik aşılama uygulanmaktadır; çalışmaya KOAH tanılı, orta-çok ağır hava akımı kısıtlaması olan 18-65 yaş arası hastalar katılabilmektedir. Çalışma Erken Faz 1 aşamasında yürütülmüş ve tamamlanmıştır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
Inclusion Criteria: 1. Written informed consent must be obtained before any assessment is performed 2. Male or female adults aged 18-65 years 3. Diagnosed with COPD according to GOLD 2016 (The ratio of post-bronchodilator forced expiratory volume in 1 second (FEV1) to force vital capacity (FVC)\<0.70 with the use of salbutamol 400ug) 4. Moderate to very severe airflow limitation (post-bronchodilator FEV1 \< 80% of the predicted normal value) 5. A documented history of at least 2 COPD exacerbation in the previous 12 months that required treatment with systemic glucocorticoids and/or antibiotics, or at least 1 exacerbation in the previous 12 months that requires hospitalization. 6. In the stable stage of COPD Exclusion Criteria: 1. Patients who have clinically significant and chronic hepatic, renal, cardiovascular and gastrointestinal abnormalities or malignant tumor (except for lung cancer) which could interfere with the assessment of the efficacy and safety of the study treatment 2. Patients who are in critical conditions 3. Patients who have had a COPD exacerbation that required treatment with antibiotics and/or systemic corticosteroids or an acute exacerbation of any other diseases in the 4 weeks prior to screening 4. Patients with concomitant pulmonary disease (including but not limited to bronchiectasis, interstitial lung disease, asthma) 5. Patients who are highly likely to be lost during the 3-month treatment and the 1-year follow up 6. Pregnant or nursing (lactating) women 7. Patients who have been vaccinated against influenza in the current year, or against Streptococcus pneumoniae within five years, or have vaccination contraindications 8. Patients who are allergic to amikacin or other aminoglycosides 9. Patients who have participated in any interventional clinical trials in the three months prior to screening 10. Patients with mental diseases or cognitive disorders which could interfere with treatment and follow-up